Brainstorm Cell Therapeutics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
BrainStorm is a late stage leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm’s most advanced product is NurOwn®, cell based Technology Platform used to produce autologous MSC-NTF cells. BrainStorm fully enrolled a Phase 3 pivotal trial in Amyotrophic lateral sclerosis (ALS) to support a BLA filing for FDA approval. Autologous MSC-NTF cells received Orphan Drug status designation from the U.S. FDA and the European Medicines Agency in ALS. BrainStorm began enrollment of a Phase 2 open-label trial of repeat intrathecal dosing of NurOwn in progressive Multiple Sclerosis (MS) in March 2019
Ticker:
BCLI
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
NurOwn
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President and Chief Medical Officer
Brainstorm Cell Therapeutics